Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

91 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Determinants of the interindividual variability in serum cytidine deaminase activity of patients with solid tumours.
Cohen R, Preta LH, Joste V, Curis E, Huillard O, Jouinot A, Narjoz C, Thomas-Schoemann A, Bellesoeur A, Tiako Meyo M, Quilichini J, Desaulle D, Nicolis I, Cessot A, Vidal M, Goldwasser F, Alexandre J, Blanchet B. Cohen R, et al. Among authors: huillard o. Br J Clin Pharmacol. 2019 Jun;85(6):1227-1238. doi: 10.1111/bcp.13849. Epub 2019 Jan 30. Br J Clin Pharmacol. 2019. PMID: 30701582 Free PMC article.
Posterior reversible encephalopathy syndrome induced by anti-VEGF agents.
Tlemsani C, Mir O, Boudou-Rouquette P, Huillard O, Maley K, Ropert S, Coriat R, Goldwasser F. Tlemsani C, et al. Among authors: huillard o. Target Oncol. 2011 Dec;6(4):253-8. doi: 10.1007/s11523-011-0201-x. Epub 2011 Nov 17. Target Oncol. 2011. PMID: 22090260 Review.
Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients.
Huillard O, Boissier E, Blanchet B, Thomas-Schoemann A, Cessot A, Boudou-Rouquette P, Durand JP, Coriat R, Giroux J, Alexandre J, Vidal M, Goldwasser F. Huillard O, et al. Expert Opin Drug Saf. 2014 May;13(5):663-73. doi: 10.1517/14740338.2014.907270. Epub 2014 Apr 3. Expert Opin Drug Saf. 2014. PMID: 24693873 Review.
Sorafenib in thyroid cancer patients: learning from toxicity.
Huillard O, Blanchet B, Boudou-Rouquette P, Thomas-Schoemann A, Wassermann J, Goldwasser F. Huillard O, et al. Oncologist. 2014 Aug;19(8):e3. doi: 10.1634/theoncologist.2014-0156. Epub 2014 Jul 22. Oncologist. 2014. PMID: 25052452 Free PMC article.
[Biotherapies in metastatic colorectal cancers in 2014].
Jouinot A, Coriat R, Huillard O, Goldwasser F. Jouinot A, et al. Among authors: huillard o. Presse Med. 2014 Oct;43(10 Pt 1):1056-66. doi: 10.1016/j.lpm.2014.03.028. Epub 2014 Jul 24. Presse Med. 2014. PMID: 25065664 Review. French.
Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients.
Narjoz C, Cessot A, Thomas-Schoemann A, Golmard JL, Huillard O, Boudou-Rouquette P, Behouche A, Taieb F, Durand JP, Dauphin A, Coriat R, Vidal M, Tod M, Alexandre J, Loriot MA, Goldwasser F, Blanchet B. Narjoz C, et al. Among authors: huillard o. Invest New Drugs. 2015 Feb;33(1):257-68. doi: 10.1007/s10637-014-0178-2. Epub 2014 Oct 25. Invest New Drugs. 2015. PMID: 25344452 Clinical Trial.
Investigational therapies up to Phase II which target PDGF receptors: potential anti-cancer therapeutics.
Arrondeau J, Huillard O, Tlemsani C, Cessot A, Boudou-Rouquette P, Blanchet B, Thomas-Schoemann A, Vidal M, Tigaud JM, Durand JP, Alexandre J, Goldwasser F. Arrondeau J, et al. Among authors: huillard o. Expert Opin Investig Drugs. 2015 May;24(5):673-87. doi: 10.1517/13543784.2015.1005736. Epub 2015 Jan 20. Expert Opin Investig Drugs. 2015. PMID: 25599887 Review.
91 results